Emanuele D'Amico

List of Publications by Year
in descending order

97 papers	3,225 citations	236612 25 h-index	174990 52 g-index
98 all docs	98 docs citations	98 times ranked	5062 citing authors

#	Article	IF	Citations
1	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1160-1203.	6.3	890
2	Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2013, 65, 509-527.	1.3	269
3	Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360.	2.9	179
4	Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis. Annals of Neurology, 2009, 66, 513-520.	2.8	132
5	Review: Patient-reported outcomes in multiple sclerosis care. Multiple Sclerosis and Related Disorders, 2019, 33, 61-66.	0.9	94
6	Lithium carbonate in amyotrophic lateral sclerosis. Neurology, 2010, 75, 619-625.	1.5	90
7	The DYMUS questionnaire for the assessment of dysphagia in multiple sclerosis. Journal of the Neurological Sciences, 2008, 269, 49-53.	0.3	85
8	Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2016, 73, 1425.	4.5	74
9	Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Sciences, 2009, 30, 193-199.	0.9	68
10	Prevalence of patient-reported dysphagia in multiple sclerosis patients: An Italian multicenter study (using the DYMUS questionnaire). Journal of the Neurological Sciences, 2013, 331, 94-97.	0.3	53
11	Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients, 2020, 12, 1389.	1.7	52
12	Late‐onset and young‐onset relapsing‐remitting multiple sclerosis: evidence from a retrospective long‐term follow‐up study. European Journal of Neurology, 2018, 25, 1425-1431.	1.7	47
13	Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory. PLoS ONE, 2016, 11, e0160261.	1.1	46
14	Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria. Journal of Neurology, 2018, 265, 828-835.	1.8	45
15	Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	43
16	The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis. Cells, 2019, 8, 1114.	1.8	40
17	Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, 91-95.	1.0	38
18	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Multiple Sclerosis Journal, 2019, 25, 399-407.	1.4	38

#	Article	IF	Citations
19	Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs. Drug Safety, 2016, 39, 1163-1174.	1.4	35
20	Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Multiple Sclerosis and Related Disorders, 2019, 27, 324-326.	0.9	35
21	Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Review of Neurotherapeutics, 2015, 15, 803-824.	1.4	30
22	Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1355-1359.	0.9	29
23	A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives. International Journal of Molecular Sciences, 2016, 17, 1725.	1.8	27
24	Clinical evolution of pure upper motor neuron disease/dysfunction (PUMMD). Muscle and Nerve, 2013, 47, 28-32.	1.0	26
25	Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879640.	1.5	26
26	Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Frontiers in Neurology, 2019, 10, 337.	1.1	26
27	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. PLoS ONE, 2012, 7, e41227.	1.1	25
28	Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives. Autoimmunity Reviews, 2019, 18, 665-672.	2.5	25
29	Dietary Phenolic Acids and Their Major Food Sources Are Associated with Cognitive Status in Older Italian Adults. Antioxidants, 2021, 10, 700.	2.2	25
30	Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients, 2021, 13, 2273.	1.7	25
31	Treatment options of cognitive impairment in multiple sclerosis. Neurological Sciences, 2010, 31, 265-269.	0.9	24
32	Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience. Multiple Sclerosis and Related Disorders, 2020, 46, 102561.	0.9	24
33	Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. Neurotherapeutics, 2021, 18, 1166-1174.	2.1	24
34	Can we define a rehabilitation strategy for cognitive impairment in progressive multiple sclerosis? A critical appraisal. Multiple Sclerosis Journal, 2016, 22, 581-589.	1.4	23
35	Management of dysphagia in multiple sclerosis: current best practice. Expert Review of Gastroenterology and Hepatology, 2019, 13, 47-54.	1.4	20
36	Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience. Journal of Neurology, 2019, 266, 411-416.	1.8	20

#	Article	IF	Citations
37	Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology, 2020, 267, 3008-3020.	1.8	19
38	Offspring Number Does Not Influence Reaching the Disability's Milestones in Multiple Sclerosis: A Seven-Year Follow-Up Study. International Journal of Molecular Sciences, 2016, 17, 234.	1.8	18
39	Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. Journal of Neurology, 2016, 263, 1802-1809.	1.8	18
40	Clinical and patient determinants of changing therapy in relapsing-remitting multiple sclerosis (SWITCH study). Multiple Sclerosis and Related Disorders, 2020, 42, 102124.	0.9	18
41	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. International Journal of Molecular Sciences, 2019, 20, 5459.	1.8	17
42	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. Environmental Research, 2020, 188, 109820.	3.7	17
43	First-line therapies in late-onset multiple sclerosis: An Italian registry study. European Journal of Neurology, 2021, 28, 4117-4123.	1.7	17
44	Exploring polypharmacy phenomenon in newly diagnosed relapsing–remitting multiple sclerosis: a cohort ambispective single-centre study. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098312.	1.1	16
45	Serum leptin levels in acromegalic patients before and during somatostatin analogs therapy. Journal of Endocrinological Investigation, 2003, 26, 1219-1224.	1.8	13
46	Risk factors in multiple sclerosis: a population-based case–control study in Sicily. Background and methods. Neurological Sciences, 2016, 37, 1931-1937.	0.9	13
47	An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety, 2019, 18, 925-948.	1.0	13
48	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	1.4	13
49	Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy. Neurological Sciences, 2020, 41, 1075-1079.	0.9	13
50	Disability may influence patient willingness to participate in decision making on first-line therapy in multiple sclerosis. Functional Neurology, 2016, 31, 21-3.	1.3	13
51	Toxoplasma gondii and multiple sclerosis: a population-based case–control study. Scientific Reports, 2020, 10, 18855.	1.6	12
52	An update on the pharmacological management of pain in patients with multiple sclerosis. Expert Opinion on Pharmacotherapy, 2020, 21, 2249-2263.	0.9	12
53	Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 802-811.	1.4	11
54	Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study. Neurological Sciences, 2019, 40, 1383-1391.	0.9	11

#	Article	IF	Citations
55	Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients. Expert Opinion on Pharmacotherapy, 2020, 21, 1449-1454.	0.9	11
56	Inpatient versus outpatient rehabilitation for multiple sclerosis patients: effects on disability and quality of life. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	10
57	A New Rail-to-Rail Second Generation Voltage Conveyor. Electronics (Switzerland), 2019, 8, 1292.	1.8	10
58	The Dysphagia in Multiple Sclerosis Questionnaire Correlates with Fiber-Optic Endoscopic Examination for Detecting Swallowing Deficits in MS. Dysphagia, 2021, 36, 192-197.	1.0	10
59	To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Review of Neurotherapeutics, 2017, 17, 847-849.	1.4	9
60	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics, 2021, 18, 905-919.	2.1	9
61	Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. Neurological Sciences, 2014, 35, 789-791.	0.9	8
62	Negative prognostic impact of MRI spinal lesions in the early stages of relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731663156.	0.5	8
63	Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. Expert Opinion on Pharmacotherapy, 2017, 18, 1553-1556.	0.9	8
64	Pharmacoeconomics of synthetic therapies for multiple sclerosis. Expert Opinion on Pharmacotherapy, 2019, 20, 1331-1340.	0.9	8
65	Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience. Frontiers in Neurology, 2020, 11, 105.	1.1	8
66	Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study. Multiple Sclerosis Journal, 2021, 27, 2284-2287.	1.4	8
67	Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. International Journal of Molecular Sciences, 2022, 23, 3829.	1.8	7
68	Cognitive impairment and â€œinvisible symptomsâ€•are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97.	0.8	6
69	Prevalence and Incidence of Multiple Sclerosis in the City of Biancavilla. Neuroepidemiology, 2019, 53, 108-114.	1.1	6
70	Gonadal Steroids and Sperm Quality in a Cohort of Relapsing Remitting Multiple Sclerosis: A Case-Control Study. Frontiers in Neurology, 2020, 11, 756.	1.1	6
71	Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Review of Neurotherapeutics, 2020, 20, 771-782.	1.4	6
72	Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab. CNS Drugs, 2020, 34, 535-543.	2.7	6

#	ARTICLE	IF	CITATIONS
73	Pregnancy outcomes in multiple sclerosis patients previously treated with cyclophosphamide. Acta Neurologica Scandinavica, 2014, 130, e41-e44.	1.0	5
74	Palliative care in progressive multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 123-127.	1.4	5
75	Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies. Neural Regeneration Research, 2022, 17, 567.	1.6	5
76	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study. PLoS ONE, 2016, 11, e0157721.	1.1	5
77	Hopelessness in Multiple Sclerosis: Psychological and Organic Correlates. Journal of Psychiatry and Psychiatric Disorders, 2019, 03, .	0.0	5
78	Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis. Frontiers in Immunology, 2022, 13, 819136.	2.2	5
79	Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. Expert Review of Neurotherapeutics, 2015, 15, 251-268.	1.4	4
80	The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. Multiple Sclerosis and Related Disorders, 2017, 17, 154-171.	0.9	4
81	Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience. Expert Review of Clinical Pharmacology, 2018, 11, 531-536.	1.3	4
82	Silicon Photomultiplier Sensor Interface Based on a Discrete Second Generation Voltage Conveyor. Sensors, 2020, 20, 2042.	2.1	4
83	Comparison of genioglossus muscle activity and efficiency of dexmedetomidine or propofol during drug-induced sleep endoscopy in patients with obstructive sleep apnea/hypopnea syndrome. European Review for Medical and Pharmacological Sciences, 2019, 23, 389-396.	0.5	4
84	A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis. Expert Opinion on Drug Safety, 2015, 14, 1157-1168.	1.0	3
85	Lack of association between Toxocara canis and multiple sclerosis: A population-based case–control study. Multiple Sclerosis Journal, 2020, 26, 258-259.	1.4	3
86	Personalized therapy in multiple sclerosis: state of art and future perspectives. Expert Review of Precision Medicine and Drug Development, 2016, 1, 353-360.	0.4	2
87	Can new chemical therapies improve the management of multiple sclerosis in children?. Expert Opinion on Pharmacotherapy, 2017, 18, 45-55.	0.9	1
88	Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial. Expert Review of Precision Medicine and Drug Development, 2017, 2, 69-71.	0.4	1
89	May baseline JCV status influence the MS clinical evolution during Natalizumab treatment? Evidence from a multicenter-2 years-prospective study. Multiple Sclerosis and Demyelinating Disorders, 2017, 2, .	1.1	1
90	Pharmacokinetic drug evaluation of daclizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 341-352.	1.5	1

#	Article	IF	Citations
91	Are oligoclonal bands associated to lower retinal layer thickness at the time of relapsing remitting multiple sclerosis diagnosis? Evidence from an exploratory study. Autoimmunity Reviews, 2019, 18, 102365.	2.5	1
92	Spinal needle and post-dural puncture headache. Neurological Sciences, 2022, 43, 1467-1468.	0.9	1
93	Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study. International Journal of Environmental Research and Public Health, 2022, 19, 6069.	1.2	1
94	Access to home palliative care services in Italy: the experience of the â€˜SAMOT Onlusâ€™ home care unit. Expert Review of Quality of Life in Cancer Care, 2017, 2, 233-234.	0.6	0
95	New treatment targets in multiple sclerosis therapy. Expert Review of Precision Medicine and Drug Development, 2019, 4, 201-203.	0.4	0
96	Exit-strategies in Natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: A multicentre comparison study. Journal of the Neurological Sciences, 2021, 429, 117769.	0.3	0
97	First-line therapies in late onset multiple sclerosis: An Italian registry study. Journal of the Neurological Sciences, 2021, 429, 118090.	0.3	0